Compare NAT & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAT | CMPS |
|---|---|---|
| Founded | 1995 | 2020 |
| Country | Bermuda | United Kingdom |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 914.8M | 778.7M |
| IPO Year | 1997 | 2020 |
| Metric | NAT | CMPS |
|---|---|---|
| Price | $4.98 | $6.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $3.25 | ★ $27.14 |
| AVG Volume (30 Days) | ★ 5.2M | 4.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.46% | N/A |
| EPS Growth | N/A | ★ 0.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $56.53 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $525.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.13 | $2.25 |
| 52 Week High | $6.34 | $8.90 |
| Indicator | NAT | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 48.58 | 43.07 |
| Support Level | $3.21 | $5.95 |
| Resistance Level | $6.34 | $7.02 |
| Average True Range (ATR) | 0.29 | 0.50 |
| MACD | -0.10 | -0.09 |
| Stochastic Oscillator | 13.22 | 3.93 |
Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.